Mechanisms of antibody-mediated insulin-like growth factor i receptor (IGF-IR) down-regulation in MCF-7 breast cancer cells

BioScience Trends

Volumn 3, Issue 4, 2009, Pages 131-138

  Ohtani, Masahiro ^a   Numazaki, Maki ^a   Yajima, Yukiko ^a   Fujita Yamaguchi, Yoko ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

Anti IGF I receptor antibodies; Breast cancer; Cancer therapy; Receptor down regulation

Indexed keywords

METHYLAMINE; MONOCLONAL ANTIBODY; SOMATOMEDIN C RECEPTOR;

ARTICLE; COATED PIT; DOWN REGULATION; DRUG EFFECT; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOBLOTTING; IMMUNOLOGY; IMMUNOPRECIPITATION; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COATED PITS, CELL-MEMBRANE; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METHYLAMINES; MICROSCOPY, FLUORESCENCE; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 77952554793     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol. 2001; 54:133-137.
2. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, LeBon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J, Fujita-Yamaguchi Y. Insulin like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants define functional specificity. EMBO J. 1986; 5:2503-2512.
3. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007; 28:20-47.
4. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer. 2005; 92:2097-2101.
5. Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta. 2006; 66:1-22.
6. LeRoith D, Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell. 2004; 5:201-202.
7. Bohula EA, Playford MP, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs. 2003; 14:669-682.
8. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007; 6:1-12.
9. Feng Y, Dimitrov DS. Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Devel. 2008; 11:178-185.
10. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist. 2008; 13:16-24.
11. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1988; 279:563-566.
12. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004; 363:1346-1353.
13. Li SL, Kato J, Paz IB, Kasuya J, Fujita-Yamaguchi Y. Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor. Biochem Biophys Res Commun. 1993; 196:92-98.
14. Li SL, Liang SJ, Guo N, Wu AM, Fujita-Yamaguchi Y. Single chain antibodies against human insulin-like growth factor-I receptor: Expression, purification, and effect on tumor growth. Cancer Immunol Immunother. 2000; 49:243-252.
15. Ye JJ, Liang SJ, Guo N, Li SL, Wu AM, Giannini S, Sachdev D, Yee D, Brünner N, Ikle D, Fujita-Yamaguchi Y. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor in vivo. Horm Metab Res. 2003; 35:836-842.
16. Sachdev S, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single chain antibody against the type I insulin-like growth factor receptor renders breast cancer cells refractory to the mitogenic effects of insulin-like growth factor-I. Cancer Res. 2003; 63:627-635.
17. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther. 2002; 1:1349-1353.
18. Jackson-Booth PG, Terry C, Lackey B, Lopaczynska M, Nissley P. Inhibition of the biologic response to insulinlike growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor downregulation. Horm Metab Res. 2003; 35:850-856.
19. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 2003; 63:8912-8921.
20. Wang Y, Hailey J, Williams D, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther. 2005; 4:1214-1221.
21. Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther. 2008; 7:2575-2588.
22. Xiong L, Kasuya J, Li SL, Kato J, Fujita-Yamaguchi Y. Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor. Proc Natl Acad Sci U S A. 1992; 89:5356-5360.
23. Soos MA, Field CE, Lammers R, Ullrich A, Zhang B, Roth RA, Andersen AS, Kjeldsen T, Siddle K. A panel of monoclonal antibodies for the type I insulinlike growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem. 1992; 267:12955-12963.
24. Kull FC Jr, Jacobs S, Su YF, Svoboda ME, Van Wyk JJ, Cuatrecasas P. Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem. 1983; 258:6561-6566.
25. Ilangumaran S, Hoessli DC. Effects of cholesterol depletion by cyclodextrin on the sphingolipid microdomains of the plasma membrane. Biochem J. 1998; 335:433-440.
26. Orlandi PA, Fishman PH. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J Cell Biol. 1998; 141:905-915.
27. Yajima Y, Sato M, Sumida M, Kawashima S. Mechanism of adult primitive mesenchymal ST-13 preadipocyte differentiation. Endocrinology. 2003; 144:2559-2565.
28. Vecchione A, Marchese A, Henry P, Rotin D, Morrione A. The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Mol Cell Biol. 2003; 23:3363-3372.
29. Kusada Y, Morizono T, Matsumoto-Takasaki A, Sakai K, Sato S, Asanuma H, Takayanagi A, Fujita-Yamaguchi Y. Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody. J Biochem (Tokyo). 2008; 143:9-19.
30. Schumacher R, Soos MA, Schlessinger J, Brandenburg D, Siddle K, Ullrich A. Signaling-competent receptor chimeras allow mapping of major insulin receptor binding domain determinants. J Biol Chem. 1993; 268:1087-1094.
31. Gustafson TA, Rutter WJ. The cysteine-rich domains of the insulin and insulin-like growth factor I receptors are primary determinants of hormone binding specificity. Evidence from receptor chimeras. J Biol Chem. 1990; 265:18663-18667.
32. Monami G, Miliozzi V, Morrione A. Grb10/Nedd4-mediated multiubiquitination of the insulin-like growth factor receptor regulates receptor internalization. J Cell Physiol. 2008; 216:426-437.
33. Broussas M, Dupont J, Gonzalez A, Blaecke A, Fournier M, Corvaira N, Goetsch L. Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int J Cancer. 2009; 124:2281-2293.
34. Romanelli RJ, LeBeau AP, Fulmer CG, Lazzarino DA, Hochberg A, Wood TL. Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt. J Biol Chem. 2007; 282:22513-22524.
35. Sehat B, Anderson S, Girnita L, Larsson O. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res. 2008; 68:5667-5677.